ClinicalTrials.gg
CompletedNCT07684937Updated Jul 6, 2026

HL-300 Ointment in Healthy Volunteers

A Phase 1 interventional study of HL-300 and HL-300 in Atopic Dermatitis, sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd. Completed. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 11 months after the study started (first participant enrolled Jun 2024, registered Jun 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

To evaluate the safety and tolerability of HL-300 ointment following single and multiple topical administrations in healthy Chinese adult volunteers.

Read the detailed description

This study is a single-center, randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase I clinical study in healthy volunteers. A total of 36 volunteers are planned to be enrolled, with 4 in Cohort 1, 8 in Cohort 2, and 12 in each of Cohort 3 and Cohort 4.

In the single ascending dose (SAD) part (Cohorts 1-3), volunteers in each cohort will receive a single dose on Day 1 (D1). Blood samples will be collected from the volunteers at the time points specified in the protocol, and volunteers will be discharged after completing the final blood collection on D8. The blood sampling timepoints for subsequent dose cohorts may be adjusted based on the results of the preceding cohorts.

In the multiple ascending dose (MAD) part (Cohort 4), volunteers will apply the study drug twice daily from D1 to D7 (the dosing frequency during the MAD period may be appropriately adjusted based on the PK characteristics of the single dose). Blood sampling timepoints will be adjusted based on the dosing results, and volunteers will be discharged to enter the safety follow-up period after completing the final blood collection.

Volunteers in different dose cohorts will be enrolled sequentially, and the next cohort will only proceed provided that the 7-day tolerability evaluation of the preceding cohort indicates safety and tolerability. Whether to add subsequent dose cohorts will be determined based on the results obtained from the completed dose cohorts.

02

Conditions studied

  • Atopic Dermatitis

Browse trials for

03

In context

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

This study's enrollment of 36 is below the median of 82 across 1,249 interventional studies indexed under Dermatitis, Atopic.

Browse Dermatitis, Atopic studies →

Lead sponsor

Hangzhou Highlightll Pharmaceutical Co., Ltd is the lead sponsor of 14 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female volunteers aged ≥ 18 and ≤ 45 years
  2. Males weighing ≥ 50 kg and females weighing ≥ 45 kg, with a (BMI) within the range of 19.0 to 26.0 kg/m² (inclusive), where BMI = weight (kg) / height² (m²);
  3. Women of (WOCBP) must confirm that they are not pregnant or lactating, and may only enter the study after a pregnancy test (e.g., based on HCG beta-subunit testing) is performed (the date of the last menstrual period must be recorded);
  4. Volunteers and their partners must voluntarily adopt effective measures for at least 6 months after the administration of the product; volunteers must have no plans to donate sperm or eggs for at least 6 months from the screening period to after administration;
  5. Volunteers must understand the form, voluntarily participate in the study, and sign the informed consent form; the informed consent form must be signed prior to the initiation of any study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Individuals with a history of malignant tumors, or any clinically severe disease (past or present) involving the circulatory, endocrine, nervous, digestive, respiratory, genitourinary, hematological, immunological, psychiatric systems, or metabolic disorders, or any other disease that may interfere with the study results;
  2. Volunteers who, in the opinion of the investigator, have skin diseases that are for the study or may interfere with the assessment of the administration site, including psoriasis, eczema, acne, atopic dermatitis, dysplastic nevi, other skin lesions, or a history of skin cancer;
  3. Individuals with a history of active tuberculosis, a history of frequent infections within 1 year prior to screening, or a history of recurrent viral infections (such as recurrent oral herpes, genital herpes, or herpes zoster) within 3 months prior to administration; those who have experienced an infection deemed clinically significant by the investigator within 1 month prior to screening, including acute or chronic infections such as local infections (abscesses, furuncles, carbuncles, etc.), respiratory tract infections, genitourinary tract infections, or systemic infections;
  4. Individuals suspected of being allergic to the drug or any of its components, or with a history of allergic diseases (e.g., allergic rhinitis, allergic asthma, etc.), drug allergy history, skin allergy history (including but not limited to allergies to adhesive patches, or contact dermatitis to metals, cosmetics, or household products), or those known to have an atopic constitution, such as a history of allergy to two or more drugs and foods.
  5. Those with vital signs (systolic blood pressure \<90 mmHg or >140 mmHg, diastolic blood pressure \<50 mmHg or >90 mmHg; heart rate \<50 bpm or >100 bpm) or abnormalities in physical examination, (ECG), chest X-ray, or laboratory tests that are clinically significant (as determined by the clinical research physician);
  6. Those whose white blood cell count, , lymphocyte count, or in the routine blood test are outside the normal reference range and are deemed clinically significant by the investigator;
  7. > 1.5 times the (ULN), or AST > 1.5 times ULN, or total > 1.5 times ULN;
  8. Those with positive test results for surface antigen (HBsAg), virus antibody (HCV-Ab), (HIV) antibody, or Treponema pallidum antibody (TP-Ab);
  9. Those with a positive dermatographia (skin scratch) test;
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Other
    HL-300 Ointment 0.25% Group

    Strength:0.25%;Dosing Days:Day 1;Ointment Dosage and Administration:2.5g, 1600 cm²;

    Drug: HL-300

  • Other
    HL-300 Ointment 0.5% Group

    Strength:0.5%;Number of Healthy Volunteers:8 (Treatment group: 6, Placebo: 2);Dosing Days:Day 1;Ointment Dosage and Administration:5g, 3200 cm²;

    Drug: HL-300

  • Other
    HL-300 Ointment 1% Group

    Strength:1.0%;Number of Healthy Volunteers:12 (Treatment group: 10, Placebo: 2);Dosing Days:Day 1;Ointment Dosage and Administration:5g, 3200 cm²

    Drug: HL-300

  • Other
    HL-300 Ointment 1% BID Group

    Strength:1.0%;Number of Healthy Volunteers:12 (Treatment group: 10, Placebo: 2);Dosing Days:Day 1-Day 7, BID;Ointment Dosage and Administration:5g, 3200 cm²

    Drug: HL-300

Interventions

  • DrugHL-300

    Number of Healthy Volunteers:4 (Treatment group: 3, Placebo\*: 1)

    Also known as: Placebo

  • DrugHL-300

    Number of Healthy Volunteers:8 (Treatment group: 6, Placebo: 2);Dosing Days:Day 1;

    Also known as: Placebo

  • DrugHL-300

    Number of Healthy Volunteers:12 (Treatment group: 10, Placebo: 2);Dosing Days:Day 1

    Also known as: Placebo

  • DrugHL-300

    Number of Healthy Volunteers:12 (Treatment group: 10, Placebo: 2);Dosing Days:Day 1-Day 7, BID;

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. To evaluate the safety and tolerability of HL-300 ointment after single and multiple topical doses in healthy adult volunteers in China

    Change from Baseline in Complete Blood Count

    Time frame: Single dose: Day3 Day 8;Multiple dose: Day7 Day14

  2. To evaluate the safety and tolerability of HL-300 ointment after single and multiple topical doses in healthy adult volunteers in China

    Change from Baseline in Blood Biochemistry

    Time frame: Single dose:Day3 Day 8;Multiple dose: Day7 Day14

  3. To evaluate the safety and tolerability of HL-300 ointment after single and multiple topical doses in healthy adult volunteers in China

    Change from Baseline in Coagulation Function

    Time frame: Single dose:Day3, Day 8;Multiple dose: Day3, Day5, Day7, Day9, Day11, Day14

  4. To evaluate the safety and tolerability of HL-300 ointment after single and multiple topical doses in healthy adult volunteers in China

    Change from Baseline in Urinalysis

    Time frame: Single dose:Day3 Day 8;Multiple dose: Day7 Day14

  5. To evaluate the safety and tolerability of HL-300 ointment after single and multiple topical doses in healthy adult volunteers in China

    Change from Baseline in U12-Lead Electrocardiogram (ECG)

    Time frame: Single-dose: Pre-dose Day1,post-dose Day1-12hour , Day2, Day3, Day8. Multiple-dose: Pre-dose Day1, Day4, Day7,post-dose Day1-12hour , Day7-12hour, Day10, Day14.

  6. To evaluate the safety and tolerability of HL-300 ointment after single and multiple topical doses in healthy adult volunteers in China

    Change from Baseline in Physical Examination

    Time frame: Single dose: Day 8; Multiple dose: Day7, Day14

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Nov 2024, 5 months.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 5 months is below that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2026
First posted
Jul 6, 2026
StartActual
Jun 14, 2024
Primary completionActual
Nov 25, 2024
CompletionActual
Nov 25, 2024
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07684937
Responsible party
Sponsor
First posted
Jul 6, 2026
Start date
Jun 14, 2024
Primary completion
Nov 25, 2024
Completion
Nov 25, 2024
Last update
Jul 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion